Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Latanoprost continuation versus discontinuation after cataract surgery in glaucoma patients
IRCT2016081329326N1Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Sep 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, double-blind trial of latanoprost in Glaucoma (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoint: Central macular thickness change from baseline. Started Sep 2016; status: completed.
02
Drugs
latanoprost
03
Conditions
Glaucoma
Beyond the preview
Go deeper on IRCT2016081329326N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2016081329326N1.